| 生物活性 |
Gamma-glutamylcysteine TFA (γ-Glu-Cys TFA) is an orally active dipeptide capable of crossing the blood-brain barrier that activates the AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways, inhibits the NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways, and modulates macrophage polarization, regulates CD36 and GLUT4 trafficking, induces glutathione synthesis, ameliorates metabolic dysfunction, reduces lipid deposition, improves glucose homeostasis, inhibits apoptosis, stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation, and ferroptosis, lowers ds-HMGB1 levels, reverses mechanical hyperalgesia, and attenuates hepatic lipid droplet formation, and can therefore be used in research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease. |
体外研究 (In Vitro) |
Gamma-glutamylcysteine TFA (0-80 μM; 24 h) 可通过抑制 JAK1/STAT1/3、AKT、MAPKs 及 NF-κB 信号通路,同时激活 AMPK/SIRT1 轴,来抑制 Raw264.7 巨噬细胞的 M1 极化。 Gamma-glutamylcysteine TFA (0-80 μM; 24 h) 可促进 Raw264.7 巨噬细胞的 M2 极化,并通过激活 IL-4/STAT6 和 AMPK/SIRT1 信号通路驱动其从 M1 向 M2 重极化。 Gamma-glutamylcysteine TFA (20-80 μM; 24 h) 可通过促进 IL-4 分泌来诱导人 Jurcat CD4+ T 淋巴细胞向 Th2 极化。 Gamma-glutamylcysteine TFA (2 mM; 6 h) 可通过核转位激活 Nrf2 信号通路,并上调鸡胚原代肠上皮细胞 (IECs) 中抗氧化靶基因和蛋白的表达。 Gamma-glutamylcysteine TFA (2 mM; 6 h) 可通过维持 Nrf2 激活,抑制鼠伤寒沙门氏菌在野生型鸡胚原代肠上皮细胞 (IECs) 中诱导的氧化应激。 Gamma-glutamylcysteine TFA (2 mM; 6 h) 可保护野生型鸡胚原代肠上皮细胞 (IECs) 免受鼠伤寒沙门氏菌 (Salmonella typhimurium) 诱导的肠屏障破坏与炎性损伤,且该保护作用依赖于 Nrf2 信号通路。 Gamma-glutamylcysteine TFA (20-80 μM; 24 h following 24 h insulin + PA pre-treatment) 可通过增加关键通路蛋白的磷酸化水平,以剂量依赖的方式激活经 Insulin (HY-P701240) + Palmitic acid (MS-A29753) (PA) 诱导产生胰岛素抵抗的 HepG2 细胞、原代小鼠肝细胞和 C2C12 肌管中的 IGF-1R/IRS1/PI3K/Akt 信号通路。 Gamma-glutamylcysteine TFA (2-4 mM; 2 h pretreatment followed by 12 h cadmium exposure) 通过下调促凋亡标志物的表达并使 Bax/Bcl-2 比值恢复正常,抑制镉诱导的 细胞中 JNK/p38 MAPK 、PI3K/Akt 信号通路信号通路的激活,从而抑制镉诱导的 PC12 细胞凋亡相关蛋白变化,抑制镉诱导的细胞凋亡,阻止镉诱导的细胞线粒体跨膜电位去极化。 Gamma-glutamylcysteine TFA (2-4 mM; 2 h pretreatment followed by 12 h cadmium exposure) 可通过降低 ROS 和脂质过氧化水平、恢复抗氧化酶活性并维持细胞内 GSH 稳态,呈剂量依赖性抑制镉诱导的 PC12 细胞氧化应激。 Gamma-glutamylcysteine TFA (0.25-16 mM; 24 h) 在孵育 24 h 后,浓度高达 4 mM 时对 BV-2 细胞无毒性,而更高浓度 (8, 16 mM) 则会以剂量依赖的方式降低细胞活力。 Gamma-glutamylcysteine TFA (2-4 mM; 30 min pretreatment, 24 h AβO exposure) 可剂量依赖性地抑制 BV-2 细胞中由 AβO 诱导的促炎介质 (TNF-α、IL-1β、NO) 的释放、促炎蛋白 (iNOS、COX-2) 的表达,抑制 AβO 诱导的氧化应激,并恢复细胞的抗氧化能力。 Gamma-glutamylcysteine TFA (4 mM; 30 min pretreatment, 6-24 h AβO exposure) 可抑制 BV-2 细胞中由 AβO 诱导的 NF-κB 信号通路激活,上调并维持 Nurr1 mRNA 及蛋白的表达,进而抑制 BV-2 细胞中 AβO 诱导的 NF-κB p65 与 iNOS 启动子的结合发挥抗炎作用。 Gamma-glutamylcysteine TFA (2-4 mM; 30 min pretreatment, 24 h AβO exposure) 呈剂量依赖性地抑制原代小鼠小胶质细胞中由 AβO 诱导的促炎介质 (TNF-α、IL-1β、NO) 的释放,抑制氧化应激,并恢复细胞的抗氧化能力。 Gamma-glutamylcysteine TFA (0.25-2 mM; 12 h) 可提高 OGD/R 处理的原代皮质神经元中的 GSH 水平、GSH/GSSG 比值、GPX 活性及细胞活力,其中 2 mM (for 12 h) 的作用效果最强。 Gamma-glutamylcysteine TFA (0.85-7 mM; 12 h) 可升高氧 - 葡萄糖剥夺与复氧 (OGD/R) 处理的 PC12 细胞中的 GSH 水平、GSH/GSSG 比值、GPX 活性及细胞活力。 Gamma-glutamylcysteine TFA (1.7-7 mM; 0-12 h, time-course 0-12 h) 可 OGD/R 处理的 PC12 细胞中 GSS 的 mRNA 和蛋白水平,促进细胞中 Nrf2 的核转位,降低 Nrf2-Keap1 的相互作用,并抑制 Keap1 的上调,降低 MDA 和 Fe2+ 水平并改善细胞活力,从而抑制细胞发生铁死亡。 Gamma-glutamylcysteine TFA (3.5 mM; 12 h, time-course 0-12 h) 可通过提高磷酸化 PKC-ε 水平激活 OGD/R 处理的 PC12 细胞中的 Nrf2。 Gamma-glutamylcysteine TFA (200 μM; 15 min pre-incubation, 24 h co-incubation with oligomeric Aβ40) 可保护原代人星形胶质细胞免受寡聚体 Aβ40 诱导的细胞毒性、凋亡、氧化应激、神经炎症以及金属蛋白酶活性失调的影响,同时恢复抗氧化状态和 GSH 水平。 Gamma-glutamylcysteine TFA (20-80 μM; 2 h pretreatment followed by 24 h ethanol exposure; 400 μM; 24 h single treatment) 可通过剂量依赖性地提高细胞活力、减少肝酶释放、抑制细胞凋亡、抑制氧化应激和线粒体损伤,以及减弱促炎信号通路激活,保护人 L02 肝细胞免受乙醇诱导的损伤。
Western Blot Analysis
| Cell Line: |
insulin + palmitic acid-induced insulin-resistant HepG2 cells, primary mouse hepatocytes, C2C12 mouse skeletal muscle myotubes |
| Concentration: |
0, 20, 40, 80 μM |
| Incubation Time: |
24 h (following 24 h insulin + PA pre-treatment) |
| Result: |
Significantly increased phosphorylation of p-IGF-1R (Tyr1135), p-IRS1 (Tyr612), p-PI3K, and p-Akt (Ser473) in a dose-dependent manner relative to insulin + PA-only treated cells across all three cell types, with significant increases observed at 20, 40, and 80 μM. |
Apoptosis Analysis
| Cell Line: |
PC12 cells |
| Concentration: |
4 mM |
| Incubation Time: |
2 h pretreatment + 12 h cadmium exposure |
| Result: |
Significantly reduced the number of TUNEL-positive PC12 cells. Decreased the percentage of apoptotic cells induced by cadmium. |
Western Blot Analysis
| Cell Line: |
PC12 cells |
| Concentration: |
4 mM |
| Incubation Time: |
2 h pretreatment + 12 h cadmium exposure |
| Result: |
Down-regulated the ratio of Bax/Bcl-2 in cadmium-treated PC12 cells. Reduced the protein levels of cytosolic cytopigment c, cleaved-caspase-9, cleaved-caspase-3, and cleaved-PARP in cadmium-treated PC12 cells. |
Western Blot Analysis
| Cell Line: |
PC12 cells |
| Concentration: |
4 mM (pretreatment for cadmium co-treatment); 4 mM (pretreatment with 4 μM anisomycin for cadmium co-treatment) |
| Incubation Time: |
2 h pretreatment + 12 h cadmium exposure; 2 h pretreatment with anisomycin + 12 h cadmium exposure |
| Result: |
Significantly inhibited cadmium-induced phosphorylation of JNK, p38, MKK3/6, and MKK7. Pretreatment with anisomycin (JNK/p38 activator) reversed the inhibitory effect on cadmium-induced PC12 cell viability loss, morphological damage, apoptosis (TUNEL and Annexin V/PI positive cells), and cleaved caspase-9, cleaved caspase-3, and cleaved PARP expression. |
Western Blot Analysis
| Cell Line: |
PC12 cells |
| Concentration: |
4 mM (pretreatment for cadmium co-treatment); 4 mM (pretreatment with 20 μM SC79 for cadmium co-treatment) |
| Incubation Time: |
2 h pretreatment + 12 h cadmium exposure; 2 h pretreatment with SC79 + 12 h cadmium exposure |
| Result: |
Significantly inhibited cadmium-induced phosphorylation of PI3K and Akt. Pretreatment with SC79 (Akt activator) reversed the inhibitory effect on cadmium-induced PC12 cell viability loss, morphological damage, apoptosis (TUNEL and Annexin V/PI positive cells), and cleaved caspase-9, cleaved caspase-3, and cleaved PARP expression. |
Western Blot Analysis
| Cell Line: |
mouse microglial BV-2 cells |
| Concentration: |
2, 4 mM |
| Incubation Time: |
30 min pretreatment; 24 h AβO exposure |
| Result: |
Dose-dependently decreased AβO-induced upregulation of iNOS and COX-2 protein expression. Caused a greater reduction in both proteins at 4 mM than at 2 mM. |
Western Blot Analysis
| Cell Line: |
mouse microglial BV-2 cells |
| Concentration: |
4 mM |
| Incubation Time: |
30 min pretreatment; 24 h AβO exposure |
| Result: |
Inhibited AβO-induced phosphorylation of IKKα and IκBα. Inhibited AβO-induced degradation of IκBα. |
|
体内研究 (In Vivo) |
Gamma-glutamylcysteine TFA (600-1200 mg/kg; p.o.; daily; ~3 days) 可显著提高 TNBS 诱导的小鼠炎症性肠病模型的存活率,减轻结肠损伤,并将巨噬细胞极化从促炎型 M1 转变为抗炎型 M2,两种剂量均显示出疗效。 Gamma-glutamylcysteine TFA (250-500 mg/kg; p.o.; daily; 8 weeks) 可呈剂量依赖性地改善血糖控制、胰岛素敏感性、β 细胞功能及肝脏脂肪变性,同时减轻 db/db 小鼠中与糖尿病相关的器官损伤。 Gamma-glutamylcysteine TFA (100-400 mg/kg/d; p.o.; daily; 20 days) 可剂量依赖性地抑制雄性 ICR 小鼠中 AβO 诱导的神经炎症。 Gamma-glutamylcysteine TFA (688 mg/kg; p.o.; single dose) 可通过激活 PKC-ε/Nrf2/GSS 通路上调 GSH,显著降低雄性 Sprague-Dawley 大鼠脑缺血/再灌注损伤诱导的脑梗死体积、神经功能障碍及神经元铁死亡。 Gamma-glutamylcysteine TFA (600 mg/kg; p.o.; once) 可显著降低 OIPN 小鼠的 DRG ds-HMGB1 水平,并逆转奥沙利铂诱导的机械性痛觉过敏。 Gamma-glutamylcysteine TFA (700-1200 mg/kg; p.o.; daily; 7 days) 可通过降低肝酶释放、恢复肝脏抗氧化水平、减轻组织病理学损伤及抑制炎症信号通路,以剂量依赖方式缓解雄性 C57BL/6JNifdc 小鼠中急性乙醇诱导的肝毒性。
| Animal Model: |
BALB/c (8-week-old male, 20-22 g, TNBS-induced colitis) |
| Dosage: |
600 mg/kg; 1200 mg/kg |
| Administration: |
p.o.; daily; ~3 days |
| Result: |
Conferred significant protection against lethality. Reversed TNBS-induced body weight loss. Reduced the increase in Disease Activity Index (DAI). Mitigated colon shortening, bleeding, and ulcerations. Lowered histological injury scores. Significantly reduced colon tissue mRNA levels of M1 markers (Inos, Il-1β). Significantly increased colon tissue mRNA levels of M2 markers (Cd206, Arg1). Significantly reduced serum TNF-α levels relative to the TNBS model group. Confirmed reduced M1 marker (iNOS, IL-1β) and increased M2 marker (CD206, ARG1) protein levels in colon tissue via Western blot and immunohistochemistry. Significantly reduced TNBS-induced phosphorylation of JAK1, STAT1, STAT3, AKT, JNK, ERK, p38, IKKα/β, and IkBα in colon lamina propria mononuclear cells. Increased phosphorylation of STAT6 and serum IL-4 levels. |
| Animal Model: |
C57BL/6J mice (male, 6 weeks old, 20-22 g); db/db mice (male, 6 weeks old, 30-35 g, spontaneous leptin receptor mutation model) |
| Dosage: |
250 mg/kg; 500 mg/kg |
| Administration: |
p.o.; daily; 8 weeks |
| Result: |
Significantly decreased food intake, food efficiency, and water intake in db/db mice at 500 mg/kg dose. Decreased water intake in db/db mice at 250 mg/kg dose. Dose-dependently decreased fasting blood glucose, serum HbA1c, serum insulin levels, and HOMA-IR index, while increased HOMA-β index in db/db mice. Dose-dependently improved glucose tolerance (reduced oral glucose tolerance test AUC) and insulin sensitivity (reduced insulin tolerance test AUC) in db/db mice. Dose-dependently improved organ coefficients (reduced liver coefficient, increased cardiac and kidney coefficients) and reduced tissue damage (cardiomyocyte degeneration, kidney glomerular/tubular damage, hepatocyte ballooning, pancreatic islet loss) in db/db mice, with 500 mg/kg treatment more effective than metformin. Dose-dependently reduced urinary MAU/ALB levels and increased hepatic glycogen content in db/db mice. Dose-dependently reduced subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) weight, and decreased adipocyte size in db/db mice. Dose-dependently reduced hepatic triglyceride (TG), total cholesterol (TC), and serum TG, TC, LDL-C levels, while increased serum HDL-C levels in db/db mice; 500 mg/kg treatment reduced hepatic TG more effectively than metformin. Dose-dependently reduced hepatic lipid droplet accumulation (Oil Red O staining) and decreased serum ALT and AST levels in db/db mice. Dose-dependently reduced hepatic CD36, PPARα, and CPT1A protein expression, and increased hepatic p-IGF-1R, p-IRS1, p-PI3K, and p-Akt protein expression in db/db mice. Showed no significant effect on body weight, fasting blood glucose, organ coefficients, or tissue histology in C57BL/6J mice at both doses. |
| Animal Model: |
ICR mice (male, 22-25 g, Alzheimer's disease model induced by intracerebroventricular administration of 2 μg AβO) |
| Dosage: |
100 mg/kg/d; 400 mg/kg/d |
| Administration: |
p.o.; daily; 20 days |
| Result: |
Suppressed AβO-induced microglial activation (reduced Iba1 fluorescence intensity in the hippocampus), and inhibited upregulation of hippocampal COX-2, iNOS, and Iba1 protein expression (100 mg/kg/d dose). Suppressed AβO-induced microglial activation with greater reduction in Iba1 fluorescence intensity than the 100 mg/kg/d dose, and exhibited stronger inhibition of AβO-induced upregulation of hippocampal COX-2, iNOS, and Iba1 protein expression compared to the 100 mg/kg/d dose (400 mg/kg/d dose). |
| Animal Model: |
Sprague-Dawley (SD) (male, 260-300 g, transient focal cerebral ischemia induced by 90-minute middle cerebral artery occlusion followed by reperfusion) |
| Dosage: |
688 mg/kg |
| Administration: |
p.o.; single dose (administered 1.5 hours after MCAO) |
| Result: |
Significantly reduced cerebral infarction volume. Significantly lowered neurological deficit scores. Significantly increased the number of Nissl-positive neurons in the ipsilateral cerebral cortex. Significantly reduced the number of FJB+/NeuN+ (dying) neurons in the cerebral cortex. Alleviated MCAO/R-induced neuronal mitochondrial damage, including reduced loss of mitochondrial cristae and outer membrane rupture. Significantly decreased cortical H2O2, malondialdehyde (MDA), and Fe2+ levels, and reduced 4-HNE-positive neuronal counts. Restored MCAO/R-induced alterations in ferroptosis-related protein and mRNA levels: increased FTH1 and GPX4, and decreased ACSL4 and TF (no effect on SLC7A11). Significantly elevated cortical GSH levels, GSH/GSSG ratio, and glutathione peroxidase (GPX) activity. Inhibited MCAO/R-induced reduction of cortical GSS mRNA and protein levels, and increased GSS/NeuN-positive neuron counts. Increased total Nrf2 and phosphorylated Nrf2 protein levels in cortical tissue, and elevated Nrf2/NeuN and p-Nrf2/NeuN-positive neuron counts. Increased phosphorylated PKC protein levels in cerebral cortical tissue. |
| Animal Model: |
C57BL/6J (male, 8-10 weeks old, 22-26 g, SPF grade, oxaliplatin-induced peripheral neuropathy model) |
| Dosage: |
600 mg/kg |
| Administration: |
p.o.; 2 hours prior to each weekly oxaliplatin injection |
| Result: |
Reduced ds-HMGB1 levels in the DRG to ~2.0 relative units. Produced a smaller reduction in serum ds-HMGB1 to ~1.6 relative units. Increased paw withdrawal thresholds to ~1.2 g, reversing oxaliplatin-induced mechanical allodynia. Reduced cold escape behavior scores to ~4.0, modestly improving cold sensitivity. Exhibited greater efficacy at reducing DRG ds-HMGB1 levels and improving pain responses than equimolar glutathione. |
| Animal Model: |
C57BL/6JNifdc (male, 6-8 weeks old, acute ethanol-induced hepatotoxicity model) |
| Dosage: |
700 mg/kg; 1200 mg/kg |
| Administration: |
p.o.; daily; 7 days |
| Result: |
Reduced ethanol-induced elevations in serum ALT, AST, and TG levels in a dose-dependent manner. Reversed ethanol-induced depletion of hepatic GSH levels. Reduced hepatic lipid droplet formation and inflammatory cell infiltration. Decreased ethanol-induced increases in hepatic protein levels of iNOS, p-p65, p-IKKα/β, and p-IκBα in a dose-dependent manner. |
|